Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jiangsu Cai Qin Technology
688182
5
Dalian Dalicap Technology
301566
US Stock MarketDetailed Quotes
ZBIO Zenas BioPharma
- 8.920
- +0.590+7.08%
Close Apr 17 16:00 ET
- 8.920
- 0.0000.00%
Post 16:24 ET
372.85MMarket Cap-2.37P/E (TTM)
9.010High8.160Low77.26KVolume8.270Open8.330Pre Close672.88KTurnover0.34%Turnover RatioLossP/E (Static)41.80MShares26.25152wk High1.19P/B206.00MFloat Cap5.83052wk Low--Dividend TTM23.09MShs Float26.251Historical High--Div YieldTTM10.20%Amplitude5.830Historical Low8.708Avg Price1Lot Size
Zenas BioPharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -90.00%5M | 5M | 0 | 0 | 0 | 50M | 0 | 50M | 0 | 0 |
| Operating revenue | -90.00%5M | --5M | --0 | --0 | --0 | --50M | --0 | --50M | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 118.92%168.89M | 144.65%60.62M | 185.09%40.98M | 110.01%39.7M | 44.49%27.58M | 2.59%77.15M | 30.49%24.78M | 14.38M | 18.91M | 19.09M |
| Selling and administrative expenses | 73.83%29.75M | 162.92%11.47M | 48.37%7.45M | 47.74%5.9M | 31.93%4.93M | 26.68%17.11M | 35.27%4.36M | --5.02M | --3.99M | --3.74M |
| -General and administrative expense | 73.83%29.75M | 162.92%11.47M | 48.37%7.45M | 47.74%5.9M | 31.93%4.93M | 26.68%17.11M | 35.27%4.36M | --5.02M | --3.99M | --3.74M |
| Research and development costs | 131.77%139.14M | 140.75%49.16M | 258.53%33.53M | 126.66%33.81M | 47.55%22.65M | -2.68%60.03M | 29.51%20.42M | --9.35M | --14.92M | --15.35M |
| Operating profit | -503.71%-163.89M | -124.48%-55.62M | -215.05%-40.98M | -110.01%-39.7M | -44.49%-27.58M | 63.90%-27.15M | -30.49%-24.78M | 35.62M | -18.91M | -19.09M |
| Net non-operating interest income expense | ||||||||||
| Other net income (expense) | 175.74%7.33M | 599.39%3.45M | 14,962.50%2.38M | 117.01%1.73M | -1,918.18%-222K | 78.05%-9.68M | 9,960.00%493K | -16K | -10.14M | -11K |
| Special income (charges) | --0 | --0 | --0 | ---- | ---- | -900.00%-10M | --0 | --0 | ---- | ---- |
| -Less：Restructuring and merger&acquisition | --0 | --0 | --0 | ---- | ---- | 900.00%10M | --0 | --0 | ---- | ---- |
| Other non- operating income (expenses) | 2,162.04%7.33M | 599.39%3.45M | 14,962.50%2.38M | 1,314.79%1.73M | -1,918.18%-222K | 101.09%324K | 9,960.00%493K | ---16K | ---142K | ---11K |
| Income before tax | -325.17%-156.56M | -114.84%-52.18M | -208.42%-38.61M | -30.74%-37.98M | -45.57%-27.8M | 69.13%-36.82M | -27.86%-24.29M | 35.61M | -29.05M | -19.1M |
| Income tax | 42.52%429K | 301K | ||||||||
| Net income | -322.87%-156.99M | -113.95%-52.6M | -208.42%-38.61M | -30.74%-37.98M | -45.57%-27.8M | 68.88%-37.12M | -29.45%-24.59M | 35.61M | -29.05M | -19.1M |
| Net income continuous Operations | -322.87%-156.99M | -113.95%-52.6M | -208.42%-38.61M | -30.74%-37.98M | -45.57%-27.8M | 68.88%-37.12M | -29.45%-24.59M | --35.61M | ---29.05M | ---19.1M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -322.87%-156.99M | -113.95%-52.6M | -208.42%-38.61M | -30.74%-37.98M | -45.57%-27.8M | 68.88%-37.12M | -29.45%-24.59M | 35.61M | -29.05M | -19.1M |
| Preferred stock dividends | 3.77M | |||||||||
| Other preferred stock dividends | 0 | 28.12M | ||||||||
| Net income attributable to common stockholders | -322.87%-156.99M | -113.95%-52.6M | -1,136.96%-38.61M | -30.74%-37.98M | -45.57%-27.8M | 68.88%-37.12M | -29.45%-24.59M | 3.72M | -29.05M | -19.1M |
| Basic earnings per share | -457.79%-11.89 | 10.84%-1.2587 | -2,448.32%-5.02 | 42.78%-0.9544 | 36.29%-0.6986 | 76.98%-2.1316 | -29.45%-1.4118 | 0.2138 | -1.6678 | -1.0965 |
| Diluted earnings per share | -457.79%-11.89 | 10.84%-1.2587 | -2,448.32%-5.02 | 42.78%-0.9544 | 36.29%-0.6986 | 76.98%-2.1316 | -29.45%-1.4118 | 0.2138 | -1.6678 | -1.0965 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
